Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers
Tachyon Therapeutics, a private, clinical-stage biotechnology company developing transformative cancer therapies against novel targets today […]
OSE Immunotherapeutics Receives New Approval for an Early Access Program for Tedopi® in Spain in Non-Small Cell Lung Cancer
OSE Immunotherapeutics SA has announced that the Spanish Drug Agency (Agencia Espanola de Medicamentos y […]
Plugging Immune Cell Leakage from Tumors Could Improve Skin Cancer Treatment
The number of specialized immune cells available for fighting skin cancer doubled when a new […]
Roche launches Two New Antibodies to Identify Key Clinical Mutations in Patients with Brain Cancer
Roche announced today the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and […]
Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors
Fore Biotherapeutics, a precision oncology company dedicated to developing innovative treatments that provide a better […]
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
MEI Pharma, a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity […]
Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities
Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving the outcomes […]
Radionetics Oncology Appoints Istvan Molnar, M.D. as Chief Medical Officer
Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for […]
CLEARA Biotech Appoints Nicholas J. Sarlis, MD, PhD as Chief Medical Officer and Head of Clinical Development
CLEARA Biotech, a preclinical-stage biotechnology company focused on developing innovative, proprietary therapies for treating different […]
Medivir Announces Pia Baumann as Chief Medical Officer (CMO)
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more